BAYZF (Bayer AG) Debt-to-Asset : 0.37 (As of Dec. 2024)

View and export this data going back to 2009. Start your Free Trial

What is Bayer AG Debt-to-Asset?

Bayer AG's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $5,451 Mil. Bayer AG's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2024 was $37,163 Mil. Bayer AG's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Dec. 2024 was $116,073 Mil. Bayer AG's debt to asset for the quarter that ended in Dec. 2024 was 0.37.

Bayer AG Debt-to-Asset Historical Data

The historical data trend for Bayer AG's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Bayer AG Debt-to-Asset Chart

Bayer AG Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Debt-to-Asset

Get a 7-Day Free Trial

0.36

0.33

0.37

Bayer AG Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Debt-to-Asset	Get a 7-Day Free Trial															0.37	-	-	-	0.37

Competitive Comparison of Bayer AG's Debt-to-Asset

For the Drug Manufacturers - General subindustry, Bayer AG's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Bayer AG's Debt-to-Asset Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Bayer AG's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Bayer AG's Debt-to-Asset falls into.

Save Embed

;

Save Embed

;

Bayer AG Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Bayer AG's Debt-to-Asset for the fiscal year that ended in Dec. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(5451.309	+	37163.351)	/	116073.298
	=	0.37

Bayer AG's Debt-to-Asset for the quarter that ended in Dec. 2024 is calculated as

Debt-to-Asset	=	Total Debt			/	Total Assets
	=	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)	/	Total Assets
	=	(5451.309	+	37163.351)	/	116073.298
	=	0.37

Bayer AG (OTCPK:BAYZF) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Bayer AG Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Bayer AG's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Bayer AG Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Bayer AG (OTCPK:BAYZF) » Definitions » Debt-to-Asset

Comparable Companies

Traded in Other Exchanges

BAYRY:USA BAYN:Romania BAY:Poland BAYN:Mexico 1BAYN:Italy BAYER:Hungary 0P6S:UK BAYNd:UK BAYN:Germany BAYN:Bulgaria BAYN:Austria

Address

Kaiser-Wilhelm-Allee 1, Leverkusen, NW, DEU, 51368

Website

https://www.bayer.com

Bayer is a German healthcare and agriculture conglomerate. Healthcare provides close to half of the company's sales and includes pharmaceutical drugs as well as vitamins and other consumer healthcare products. The firm's crop science business sells seeds, pesticides, herbicides, and fungicides, which was expanded through its 2018 acquisition of Monsanto.